Oncolytics Biotech Inc ONCY

$0.63 -0.01 (-1.59%)

Valuation

Market cap
81,760,000
Revenue TTM
$0
Net income TTM
$-28,760,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
611,800
Avg volume
876,066
Day's range
$0.62 – $0.65
Shares out
127,511,000
Stochastic %K
6%
Beta
1.15
Analysts
Strong Sell
Price target
$4.42

Price

Company profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply i...

Show more

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
403 670 7377
Website
https://oncolyticsbiotech.com
Address
4350 Executive Drive, Suite 325, San Diego, United States

Latest news

Stocktwits

FoxM07 Oct 2, 10:36 PM
$ONCY
0 replies
FoxM07 Oct 2, 10:36 PM
$ONCY
0 replies
Notable_Ex Oct 2, 10:29 PM
$ONCY
0 replies
SageSpirits Oct 2, 9:40 PM
$ONCY
0 replies
Arrankar2099 Oct 2, 8:57 PM
$ONCY
0 replies
NoName_1 Oct 2, 6:01 PM
$ONCY past performance of other stocks similar to oncy does NOT mean this stock will do the same. I guess folks have to cling to some kind of hope...
0 replies
prismmarketview Oct 2, 5:54 PM
A week of sharp turns across the PRISM Emerging Biotech Index: 48-month AMT-130 data from $QURE , a $110 million raise at $PYXS , a November 22 PDUFA date ahead for $CAPR , a year-end colorectal update planned at $ONCY and a restructuring at $FHTX . https://prismmarketview.com/a-week-of-sharp-turns-across-the-prism-emerging-biotech-index/
0 replies
aaron03 Oct 2, 5:03 PM
$ONCY I'm a staunch supporter of $ONCY, but I must admit, owning this stock is frustrating as hell. What a horrible dip in the share price! Everyone preaches patience, but we've been languishing in this range for many years now. And that's just facts. I think we hit $3/share back in 2023. And that was for a brief moment
2 replies